Putting an End to Heart Attacks by Editing Human DNA
By Angelica Peebles,
Bloomberg
| 05. 06. 2022
Patrick J. Lynch, medical illustrator,
CC BY 2.5 <>, via Wikimedia Commons
Even after decades of drug breakthroughs aimed at preventing heart attacks, they remain the world’s leading cause of death. The pills and injections on the market do the job of lowering the cholesterol that clogs blood vessels and puts people at risk of a heart attack. But not everyone has access to them, and some won’t stick to treatment plans that can last the rest of their lives. Verve Therapeutics Inc. is proposing a radical solution: altering a person’s genome—the body’s instruction manual—to stop the buildup of bad cholesterol. “We’re on the cusp of potentially transforming that model to a one-and-done treatment,” says Sekar Kathiresan, chief executive officer of the Cambridge, Mass.-based company.
Verve plans to initially target those who’ve already had a heart attack because of extremely high cholesterol caused by a hereditary condition known as familial hypercholesterolemia, which affects 31 million people globally. If it works to reduce low-density lipoprotein (LDL), or “bad,” cholesterol in that group, the company would look to widen the treatment... see more
Related Articles
A Eugenics Society poster (1930s) from the
Wellcome Library Eugenics Society Archive via Wikimedia
On a Saturday afternoon in May, Payton S. Gendron shot 13 people, almost all Black, at a supermarket in Buffalo, killing 10. This was hardly an isolated incident: It was one of over 200 mass shootings so far this year. Only 10 days later, at least 21 people died in a school shooting at Uvalde, Texas. That killer was apparently a lonely, bullied 18-year-old with a...
By Michael Eisenstein , Nature | 05.09.2022
Two companies, Beam Therapeutics and Verve Therapeutics, are leading the charge of base editing therapies to the clinic. Last November, Beam got the green light from the US Food and Drug Administration (FDA) for its upcoming BEACON-101 trial that will...
By Kevin Davies, Genetic Engineering and Biotechnology News | 05.18.2022
WASHINGTON, DC — In his current role as President Biden’s acting scientific advisor, Francis Collins, MD, PhD, is dealing with a wide range of issues from semiconductor shortages to wildfires. “But my heart is in what you are all doing...
By Kathryn Paige Harden et al., The New York Review | 05.25.2022
In response to:
Why Biology Is Not Destiny from the April 21, 2022 issue
To the Editors:
Marcus Feldman and Jessica Riskin did not like my book. Or rather, they did not like a book called The Genetic Lottery...